Schaeffers Research
31 Mar 2026, 19:40 UTC · 30w ago
Options Traders Pick Up Pharma Stock After Eli Lilly Buyout
Impact · against what's priced in
CNTA shares are correcting toward the $6.3 billion acquisition value established by Eli Lilly, with analyst downgrades suggesting limited further upside. LLY is diversifying its metabolic portfolio into sleep disorder treatments, though the impact on its valuation is marginal relative to its scale.
- CNTA+1.00
No priced-in read yet
- In context
The acquisition by Eli Lilly for $6.3 billion has driven shares up over 40% to $39.90, creating a concrete floor based on the buyout price.
Read from the article alone
Search tags
